Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic cough | Discovery | - | 05 Sep 2024 | |
Digestive System Disorders | Discovery | - | 05 Sep 2024 | |
Endocrinology and Metabolic Disease | Discovery | - | 05 Sep 2024 | |
Immune System Diseases | Discovery | - | 05 Sep 2024 | |
Infectious Diseases | Discovery | - | 05 Sep 2024 | |
Ischemia | Discovery | - | 05 Sep 2024 | |
Neoplasms | Discovery | - | 05 Sep 2024 | |
Nervous System Diseases | Discovery | - | 05 Sep 2024 | |
Other Diseases | Discovery | - | 05 Sep 2024 | |
Urogenital Diseases | Discovery | - | 05 Sep 2024 |